Cover Image

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

Abstract Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The phase III EXPLORER‐HCM (NCT03470545) study used a dose‐titration scheme based on mavacamten exposu...

Full description

Saved in:
Bibliographic Details
Main Authors: Samira Merali (Author), David H. Salinger (Author), Maria Palmisano (Author), Amy J. Sehnert (Author), Neelima Thanneer (Author), Hyunmoon Back (Author), Julie D. Seroogy (Author), Daniel D. Gretler (Author), Amit Roy (Author), Vidya Perera (Author)
Format: Book
Published: Wiley, 2024-09-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items